• Ronald Brazg, M.D., F.A.C.E.
• Leslie Klaff, M.D., Ph.D., F.R.C.P., F.A.C.E.
• Allen Sussman, M.D.

Leslie J. Klaff, M.D., Ph.D., F.R.C.P., F.A.C.E.

Personal

Education

Additional Degrees

Postgraduate Training

Faculty Positions

Endocrine and Internal Medicine Practice

Hospital Positions

Hospital Medical Staff

Honors

Board Certifications

Medical Licensure

Professional Organizations

Special National Responsibility

Special Local Responsibility

Clinical Research Projects

Bibliography

1. Klaff LJ, Levin PJ, Potgieter PD, Losman JG, Nochomovitz LE, and Ferguson AD: Treatment of paraquat poisoning with the membrane oxygenator: a case report. S Afr Med J 51:203-205, 1977.
2. Klaff LJ, Vinik AI, Berelowitz M and Jackson WPU: Circulating antibodies in diabetics treated with monocomponent and conventional insulin. S Afr Med J 54:149-153, 1978.
3. Levin PJ, Klaff LJ, Rose AG, and Ferguson AD: Pulmonary effects of contact exposure to paraquat: a clinical and epidemiological study. Thorax 34:150-160, 1979.
4. Klaff LJ, Vinik AI, Jackson WPU, Malan E, Kernoff L, and Jacobs P: A comparison of the effects of the sulfonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet functions. S Afr Med J 56:247-250, 1979.
5. Coetzee J, Klaff LJ, and Epstein S: The measurement of human serum parathyroid hormone in disorders of calcium metabolism and during administration of certain gut hormones. S Afr Med J 57:165-170, 1980.
6. Levitt NS, Vinik AI, Sive AA, Klaff LJ, and Phillips C: A double-blind cross-over trial of synthetic gonadotrophin-releasing hormone (LHRH) in impotent male diabetics. S Afr Med J 57:701-704, 1980.
7. Klaff LJ, Hudson A, Sheppard M, and Tyler M: In vitro release of cholecystokinin octapeptide-like immuno-reactivity from rat brain synaptosomes. S Afr Med J 59:158-160, 1981.
8. Klaff LJ, Kernoff L, Vinik AI, Jackson WPU, and Jacobs P: Sulphonylureas and platelet function. American J Med 70:627-730, 1981.
9. Wright JP, Young GO, Klaff LJ, Weers LA, Price SK, and Marks IN: Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma. Gastroenterology 82:263-267, 1982.
10. Millar RP, Klaff LJ, Barron J, Levitt NS, and Ling N: Somatostatin-28 inhibits Gn-RH-stimulated gonadotrophin secretion in man. Clin Endocrinol 17:103-107, 1982.
11. Klaff LJ, Hudson AM, Paul M, and Millar RP: A method for studying synaptosomal release of neurotransmitter candidates as evaluated by studies on cortical cholecystokinin octapeptide release. Peptides 3:155-161, 1982.
12. Klaff LJ, Barron JL, Levitt NS, Millar RP, and Ling N: Somatostatin-28 inhibits thyroid-stimulating hormone release in man. S Afr Med J 62:929-930, 1982.
13. Millar RP, Klaff LJ, Barron JL, Levitt NS, and Ling N: Somatostatin-28 and somatostatin-14 suppression of arginine-, insulin-, and TRH-stimulated GH & prolactin secretion in man. Clin Endocrinol 18:277-285, 1983.
14. Mee AS, Klaff LJ, Girdwood A, Paul M, Tyler M, and Marks IS: A comparative study of pancreatic polypeptide secretion endocrine and exocrine function and structural damage in chronic alcohol induced pancreatitis (CAIP). Gut 24:642-647, 1983.
15. Maze SS, Klaff LJ, and Yach D: Syndrome of inappropriate antidiuretic hormone secretion in association with herpes zoster of the chest wall. S Afr Med J 63:735-736, 1983.
16. Klaff LJ, Barron JL, Levitt NS, Ling N, and Millar RP: Inhibition of pancreatic hormone secretion by somatostatin-28 and somatostatin-14 in man. Acta Endocrinologica 104:91-95, 1983.
17. Barron JL, Klaff LJ, Levitt NS, Ling N, and Millar RP: Arginine hydrochloride stimulation of serum potassium and aldosterone is enhanced by somatostatin-28. Acta Endocrinologica 105:407-410, 1984.
18. Koeslag JH, Levinrad LI, Klaff LJ: Pancreatic polypeptide response to exercise: Effect of alanine and glucose ingestion in carbohydrate-starved athletes. S Afr Med J 67:884-887, 1985.
19. Roost R, Wright JP, Young GO, Lipshitz EM, Klaff L, Isaacs S, and Marks IN: The effect of aspirin and anti-ulcer drugs on gastric mucosal prostaglandin E. S Afr Med J 70:594-597, 1986
20. Johnston C, Raghu P, McCulloch DK, Beard JC, Ward WK, Klaff LJ, McKnight B, Bergman RN, Palmer JP: Beta cell function and insulin sensitivity in non-diabetic HLA identical siblings of insulin dependent diabetics. Diabetes 36:829-837, 1987.
21. Klaff LJ and Taborsky GJ Jr: Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes 36:592-596, 1987.
22. Klaff LJ, Tamborlane WV, Cleary PA, STEffes MW, and Becker DJ: For the DCCT Research Group: Effects of age, duration and treatment of IDDM on residual B-cell function: Observations during eligibility testing for the diabetes control and complications trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1987.
23. Klaff LJ and Taborsky GJ Jr: The role of pancreatic somatostatin in determining the glucagon response to arginine and morphine. Am J Physiol 252:E751-E755, 1987.
24. Dent DM, Miller JL, Klaff L, and Barron J: The incidence and causes of hypercalcaemia. Postgrad Med J 63:745-750, 1987.
25. McCulloch DM, Raghu PK, Johnston C, Klaff LJ, Kahn SE, Beard JC, Ward WK, Benson EA, Koerker DJ, Bergman RN, Palmer JP: Defects in beta cell function and insulin sensitivity in normoglycemic streptozocin treated baboons: a model of preclinical insulin dependent diabetes. J Clin Endocrinol Metab 67:785-792, 1988.
26. Sutton M, Klaff LJ, Asplin CM, Clemons P, Tatpati O, Lyen K, Raghu P, Baker L, Guthrie R, Sperling M, and Palmer JP: Insulin autoantibodies at diagnosis of insulin dependent diabetes--effect on the antibody response to insulin treatment. Metabolism 37:1005-1007, 1988.
27. Klaff LJ, Dunning BE, and Taborsky GJ Jr: Somatostatin-28 does not regulate islet function in the dog. Endocrinology 123:2668-2674, 1988.
28. Willcox PA, Immelman EJ, Barron JL, Klaff LJ, Harries-Jones EP, Hainsworth M, and Millar RP: Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycemia and ketoacidosis. Quart J Med 255:559-571, 1988.
29. McCulloch DK, Raghu PK, Koerker DJ, Palmer JP, and Klaff LJ: Responses of the pancreatic A-cell during hypoglycemia hyperglycemia are dependent on the B-cell. Metabolism 38:702-709, 1989.
30. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauseth RS, Benson EA, Nepom GT, Shewey L, and Palmer JP: Nonprogression of subclinical B-cell dysfunction among first-degree relatives of IDDM patients: 5-year follow-up of Seattle study. Diabetes 39:549-556, 1990.
31. Markholst H, Klaff LJ, Kloppel G, Lernmark A, Mordes JP, and Palmer J: Lack of systemically found insulin autoantibodies in spontaneously diabetic BB rats. Diabetes 39:720-727, 1990.
32. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ Jr, and Porte D Jr: Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 71:797-805, 1990
33. Greenbaum CJ, Havel PJ, Taborsky GJ Jr, and Klaff LJ: Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 88:767-773,1991.
34. Hegewald MJ, Schoenfeld SL, McCulloch DK, Greenbaum CJ, Klaff LJ, and Palmer JP: Increased specificity and sensitivity of insulin antibody measurements in autoimmune thyroid disease and type I diabetes. J Immunol Meth 154: 61-68,1992.
35. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff LJ, Peterson J, Gottlieb A: Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39:492-499, 1996.
36. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-1671, 2000.
37. Ehlers MR, Klaff LJ, D’Alessio DA, Brazg R, Kay HD, Harley R, Mathison A, Schneider R: Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res 35:611-6, 2003.
38. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 26: 2063-8, 2003.
39. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E: Postprandial vs preprandial dosing of biphasic insulin aspart in elderly patients with type 2 diabetes. Diabetes Res and Clin Practice 66:23-9, 2004.

Books, Chapters, Editorials, & Educational Publications (Non-Peer Reviewed)

1. Klaff LJ, Sheppard M, Hudson AM, Tyler M, and Vinik AI: Cholecystokinin-octapeptide-like immunoreactivity in rat central nervous system. In: Neuropeptides, Biochemical & Physiological Studies, edited by RP Millar. Churchill Livingstone, Edinburgh, 1981, pp 87-96.
2. Klaff LJ, Vinik AI, and Heldsinger A: Acid secretagogue potencies and interactions in the activation of carbonic anhydrase in guinea pig parietal cells. In: Neuropeptides, Biochemical & Physiological Studies, edited by RP Millar. Churchill Livingstone, Edinburgh, 1981, pp 336-343.
3. Klaff LJ, Kernoff L, Vinik AI, Jackson WPU, Jacobs P: Sulphonylureas and platelet function. In: Diabetes Mellitus, edited by JS Skyler and GF Cahill Jr. Yorke Medical Books, USA, 1981, pp 152-155.
4. Millar RP, Klaff LJ, and Barron JL: The new hypothalamic releasing factors (editorial). S Afr Med J 62:924-925, 1982.
5. Klaff LJ and Sive AA: Continuous subcutaneous insulin infusion (editorial). S Afr Med J 63:61-62, 1983.
6. Guest Editor, South African Journal of Continuing Medical Education, Vol 1, No 3, 1983. Subject: Diabetes Mellitus. (a) Kahn SE and Klaff LJ: The importance of metabolic control in diabetes mellitus, pp 15-23. (b) Klaff LJ and Sive AA: Factors in the genesis of diabetes mellitus, pp 80-84.
7. Clinical Discussant, Clinicopathological Conference. Post-abortal fever and shock. S Afr Med J 63:444-447, 1983.
8. Klaff LJ: Computer program. Diabetes mellitus: an update on outpatient evaluation and management 1985. CME Inc. and University of Washington, Seattle.
9. Klaff LJ and Palmer JP: Risk for developing cardiovascular risk factor: glucose intolerance. In: Cardiology clinics: risk for developing cardiovascular risk factors and adverse effects of risk factor reduction, edited by FH Messerlio and C Amodeo. W.B. Saunders Co., Philadelphia, 1986, pp 67-73